The Future of Onco-Cardiology: We Are Not Just "Side Effect Hunters"

Circ Res. 2016 Sep 30;119(8):896-9. doi: 10.1161/CIRCRESAHA.116.309573.

Abstract

Cancer treatments in general share various detrimental effects in common, especially upregulation of cardiovascular risk factors. Therefore, the science of onco-cardiology should not be restricted in scope to the side effects of each specific cancer drug. In particular, premature aging induced by cancer treatment may contribute to the chronic health problems of cancer survivors.

Keywords: anthracycline; cancer survivors; cardiotoxicity; heart failure; premature aging; survivors.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects*
  • Cardiology / trends*
  • Cardiotoxicity / genetics
  • Cardiotoxicity / prevention & control*
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / prevention & control
  • Forecasting
  • Humans
  • Medical Oncology / trends*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Telomere Shortening / drug effects
  • Telomere Shortening / physiology

Substances

  • Antineoplastic Agents